Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlordiazepoxide
Drug ID BADD_D00432
Description An anxiolytic benzodiazepine derivative with anticonvulsant, sedative, and amnesic properties. It has also been used in the symptomatic treatment of alcohol withdrawal.
Indications and Usage For the management of anxiety disorders or for the short-term relief of symptoms of anxiety, withdrawal symptoms of acute alcoholism, and preoperative apprehension and anxiety.
Marketing Status approved; illicit; investigational
ATC Code N05BA02
DrugBank ID DB00475
KEGG ID D00267
MeSH ID D002707
PubChem ID 2712
TTD Drug ID D06BEP
NDC Product Code 71554-014; 61919-593; 12828-0006; 48087-4402; 64330-082
UNII 6RZ6XEZ3CR
Synonyms Chlordiazepoxide | 7-Chloro-N-methyl-5-phenyl-3H-1,4-benzodiazepin-2-amine 4-oxide | 7 Chloro N methyl 5 phenyl 3H 1,4 benzodiazepin 2 amine 4 oxide | Methaminodiazepoxide | 7-Chloro-2-methylamino-5-phenyl-3H-1,4-benzodiazepine-4-oxide | 7 Chloro 2 methylamino 5 phenyl 3H 1,4 benzodiazepine 4 oxide | Chlordiazepoxide Hydrochloride | Hydrochloride, Chlordiazepoxide | Chlordiazepoxide Monohydrochloride | Monohydrochloride, Chlordiazepoxide | Librium | Chlozepid | Elenium | Chlordiazepoxide Hydrobromide | Hydrobromide, Chlordiazepoxide | Chlordiazepoxide Perchlorate | Perchlorate, Chlordiazepoxide
Chemical Information
Molecular Formula C16H14ClN3O
CAS Registry Number 58-25-3
SMILES CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Loss of consciousness17.02.04.004--Not Available
Menstruation irregular21.01.01.005; 05.05.01.008--
Muscle spasms15.05.03.004--
Myalgia15.05.02.001--
Nausea07.01.07.001--
Oedema14.05.06.010; 08.01.07.006--Not Available
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Pruritus23.03.12.001--
Pyrexia08.05.02.003--
Rash23.03.13.001--Not Available
Rash erythematous23.03.13.029--Not Available
Rash macular23.03.13.003--Not Available
Rash maculo-papular23.03.13.004--
Restlessness19.11.02.002; 17.02.05.021--
Shock24.06.02.002--Not Available
Skin reaction23.03.03.013; 10.01.03.019--Not Available
Somnolence19.02.05.003; 17.02.04.006--
Suicide attempt19.12.01.004--
Syncope02.11.04.015; 17.02.04.008; 24.06.02.012--
Tachycardia02.03.02.007--Not Available
Tremor17.01.06.002--
Urticaria23.04.02.001; 10.01.06.001--
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Disturbance in sexual arousal19.08.04.003--Not Available
Blood disorder01.05.01.004--Not Available
Alcohol interaction08.06.03.003--Not Available
The 2th Page    First    Pre   2    Total 2 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene